Kayla Dye, R.Ph., Pharm.D.

Dr. Kayla Dye joined CTEP’s Pharmaceutical Management Branch in 2021. She manages a portfolio of CTEP IND agents, contributes to the management of the NCI Formulary, and supports the NRG Oncology clinical trials group. She also assisted in the development and implementation of the electronic accountability system AURORA.

Prior to joining NCI, Dr. Dye was the lead investigational drug pharmacist for Cancer Treatment Centers of America in Phoenix, where she started a concomitant medication review program, supported the establishment of an Institutional Biosafety Committee and NCI program to expand clinical trial operations, and worked on several first-in-human clinical trials.